Celling Biosciences Release: Acquisition of Devices, Methods and Intellectual Property Support Leadership Position in Regenerative Therapies

AUSTIN, Texas, July 22, 2013 /PRNewswire/ -- On Wednesday, July 17th, Celling Biosciences made an asset acquisition of devices, proprietary methods and intellectual property from Orogen Biosciences. Orogen, based out of Sarasota, Florida, was an early innovator in processing platelet rich plasma (PRP) and concentrating growth factors and cytokines to optimize the most effective and efficient methods for providing therapeutic treatments with a patient's own tissue. With this acquisition, Celling is furthering its position as a leader of point of care, autologous cell therapy.

Celling is focused on the three pillars of regenerative medicine (cells, substrates, and signals) known to enhance the environment for tissue repair, regeneration, and revascularization. The devices (OPC and ACE) and methods from Orogen provide physicians with access to a patient's own growth factors and proteins to support the healing cascade. There is a growing body of evidence in the literature of the role growth factors play in optimizing the healing in multiple pathologies across medicine. The OPC device allows physicians to process autologous plasma at the point of care to deliver concentrated growth factors when compared to currently marketed options. The ACE device is a unique technology that produces an enriched preparation of growth factors without the presence of white blood cells, red blood cells or platelets.

Additionally, Celling has acquired methods and devices for delivering allogeneic products to the veterinary market. Based on the short and long term success of these products in treating horses and canines in soft tissue repair, Celling will be well positioned to penetrate the veterinary market which is leading human efforts into the emerging market of regenerative medicine.

Celling has begun the process of transitioning Orogen revenues, opening a Florida office and launching devices to the market within the next quarter. "We believe this is a unique opportunity for Celling to keep building our product and services portfolio in the autologous space. We continue to expand our registered nurse service model across the country anticipating the orchestrated event in cell therapy between physicians and technology providers. This acquisition is another step in adding sophistication to the process," says Kevin Dunworth, CEO and Founder of Celling Biosciences. We had a number of companies approach us about acquiring Orogen's intellectual property but we were waiting on the right fit both culturally and philosophically based on who we believed to be a leader in cell therapy innovation. "We are extremely excited about this development and are confident that Celling Biosciences has the vision to create significant value in the regenerative medicine space," says Ryan Brandt, President of Orogen.

About Celling BiosciencesCelling Biosciences is an Austin, Texas based company working closely with world leaders in academia, medicine, scientists and engineers to research and develop innovative technologies in the emerging field of regenerative medicine. Celling's product-offering focuses on autologous cell therapy and the devices and services that compliment these procedures. For more information please visit: www.cellingbiosciences.com.